Titre : Thymocytes

Thymocytes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Hepatitis B virus
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Thymocytes : Questions médicales les plus fréquentes", "headline": "Thymocytes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Thymocytes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-03", "dateModified": "2025-03-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Thymocytes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cellules", "url": "https://questionsmedicales.fr/mesh/D002477", "about": { "@type": "MedicalCondition", "name": "Cellules", "code": { "@type": "MedicalCode", "code": "D002477", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11" } } }, "about": { "@type": "MedicalCondition", "name": "Thymocytes", "alternateName": "Thymocytes", "code": { "@type": "MedicalCode", "code": "D060168", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Lie Wang", "url": "https://questionsmedicales.fr/author/Lie%20Wang", "affiliation": { "@type": "Organization", "name": "Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, China." } }, { "@type": "Person", "name": "Ravshan Z Sabirov", "url": "https://questionsmedicales.fr/author/Ravshan%20Z%20Sabirov", "affiliation": { "@type": "Organization", "name": "Institute of Biophysics and Biochemistry, National University of Uzbekistan, Tashkent, Uzbekistan." } }, { "@type": "Person", "name": "Chao Chen", "url": "https://questionsmedicales.fr/author/Chao%20Chen", "affiliation": { "@type": "Organization", "name": "Special Key Laboratory of Gene Detection and Therapy of the Guizhou Province, Zunyi Medical University, Zunyi, China." } }, { "@type": "Person", "name": "Lin Xu", "url": "https://questionsmedicales.fr/author/Lin%20Xu", "affiliation": { "@type": "Organization", "name": "Special Key Laboratory of Gene Detection and Therapy of the Guizhou Province, Zunyi Medical University, Zunyi, China, xulinzhouya@163.com." } }, { "@type": "Person", "name": "Pilar López-Nieva", "url": "https://questionsmedicales.fr/author/Pilar%20L%C3%B3pez-Nieva", "affiliation": { "@type": "Organization", "name": "Genome Dynamics and Function Program, Genome Decoding Department, Severo Ochoa Molecular Biology Center (CBMSO), CSIC-Madrid Autonomous University, 28049 Madrid, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Plerixafor and resatorvid inhibit hepatitis B virus", "datePublished": "2023-02-20", "url": "https://questionsmedicales.fr/article/36891156", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fcimb.2023.1118801" } }, { "@type": "ScholarlyArticle", "name": "Hepatitis B Virus Research in South Africa.", "datePublished": "2022-08-31", "url": "https://questionsmedicales.fr/article/36146747", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/v14091939" } }, { "@type": "ScholarlyArticle", "name": "Occult Hepatitis B Virus Infection: An Update.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35891484", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/v14071504" } }, { "@type": "ScholarlyArticle", "name": "Mutations in the S gene of hepatitis B virus in three generations of patients with chronic hepatitis B.", "datePublished": "2023-06-12", "url": "https://questionsmedicales.fr/article/37308753", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11262-023-02012-z" } }, { "@type": "ScholarlyArticle", "name": "Chronic Hepatitis B Virus: What an Internist Needs to Know: Serologic Diagnosis, Treatment Options, and Hepatitis B Virus Reactivation.", "datePublished": "2023-02-20", "url": "https://questionsmedicales.fr/article/37001946", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.mcna.2022.12.002" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Thymocytes", "item": "https://questionsmedicales.fr/mesh/D060168" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Thymocytes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Thymocytes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Thymocytes", "description": "Comment diagnostiquer une anomalie des thymocytes ?\nQuels examens sont utilisés pour évaluer les thymocytes ?\nLes tests génétiques sont-ils utiles pour les thymocytes ?\nPeut-on évaluer la fonction des thymocytes ?\nQuels marqueurs sont utilisés pour identifier les thymocytes ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Hepatitis+B+virus&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Thymocytes", "description": "Quels symptômes indiquent un problème avec les thymocytes ?\nLes anomalies des thymocytes causent-elles des symptômes spécifiques ?\nComment les thymocytes affectent-ils la santé globale ?\nLes symptômes d'une maladie des thymocytes sont-ils visibles ?\nLes symptômes varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Hepatitis+B+virus&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Thymocytes", "description": "Comment prévenir les maladies liées aux thymocytes ?\nY a-t-il des mesures préventives spécifiques ?\nLes dépistages réguliers sont-ils recommandés ?\nL'alimentation influence-t-elle la santé des thymocytes ?\nLe stress a-t-il un impact sur les thymocytes ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Hepatitis+B+virus&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Thymocytes", "description": "Quels traitements existent pour les anomalies des thymocytes ?\nLa transplantation de thymus est-elle une option ?\nLes traitements ciblent-ils spécifiquement les thymocytes ?\nLes thérapies biologiques sont-elles efficaces ?\nLes traitements sont-ils personnalisés selon le patient ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Hepatitis+B+virus&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Thymocytes", "description": "Quelles complications peuvent survenir avec des thymocytes anormaux ?\nLes troubles auto-immuns sont-ils liés aux thymocytes ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Hepatitis+B+virus&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Thymocytes", "description": "Quels sont les facteurs de risque pour les anomalies des thymocytes ?\nL'âge influence-t-il le risque d'anomalies thymiques ?\nLes maladies génétiques augmentent-elles le risque ?\nLe mode de vie joue-t-il un rôle dans le risque ?\nLes expositions environnementales sont-elles un facteur ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Hepatitis+B+virus&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des thymocytes ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies du thymus peuvent révéler des anomalies." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer les thymocytes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie par résonance magnétique et les analyses cytologiques sont courantes." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour les thymocytes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent identifier des anomalies génétiques affectant le développement des thymocytes." } }, { "@type": "Question", "name": "Peut-on évaluer la fonction des thymocytes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests fonctionnels mesurant la réponse immunitaire peuvent être effectués." } }, { "@type": "Question", "name": "Quels marqueurs sont utilisés pour identifier les thymocytes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs CD4 et CD8 sont souvent utilisés pour caractériser les thymocytes." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec les thymocytes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des infections fréquentes et une immunodéficience peuvent signaler des problèmes." } }, { "@type": "Question", "name": "Les anomalies des thymocytes causent-elles des symptômes spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des troubles auto-immuns et des lymphomes." } }, { "@type": "Question", "name": "Comment les thymocytes affectent-ils la santé globale ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des thymocytes dysfonctionnels peuvent compromettre la réponse immunitaire." } }, { "@type": "Question", "name": "Les symptômes d'une maladie des thymocytes sont-ils visibles ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être subtils, souvent révélés par des infections récurrentes." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants peuvent présenter des symptômes plus marqués." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux thymocytes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain et des vaccinations peuvent aider à prévenir les infections." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives spécifiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les expositions aux agents pathogènes et maintenir une bonne hygiène." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, surtout pour les personnes à risque d'immunodéficience." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle la santé des thymocytes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir la fonction immunitaire et des thymocytes." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur les thymocytes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter la fonction des thymocytes et l'immunité." } }, { "@type": "Question", "name": "Quels traitements existent pour les anomalies des thymocytes ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des immunosuppresseurs et des thérapies géniques." } }, { "@type": "Question", "name": "La transplantation de thymus est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être envisagée pour les patients avec des déficits immunitaires sévères." } }, { "@type": "Question", "name": "Les traitements ciblent-ils spécifiquement les thymocytes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains traitements visent à restaurer la fonction des thymocytes." } }, { "@type": "Question", "name": "Les thérapies biologiques sont-elles efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent moduler la réponse immunitaire et améliorer la fonction des thymocytes." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés selon le patient ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des thymocytes anormaux ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des infections graves et des cancers comme les lymphomes peuvent se développer." } }, { "@type": "Question", "name": "Les troubles auto-immuns sont-ils liés aux thymocytes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des thymocytes dysfonctionnels peuvent contribuer à des maladies auto-immunes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être traitées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent réduire la qualité de vie en augmentant la susceptibilité aux infections." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être fréquentes chez les personnes avec des anomalies thymiques." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies des thymocytes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux et certaines infections virales augmentent le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'anomalies thymiques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées sont plus à risque." } }, { "@type": "Question", "name": "Les maladies génétiques augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies génétiques peuvent prédisposer à des anomalies des thymocytes." } }, { "@type": "Question", "name": "Le mode de vie joue-t-il un rôle dans le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut augmenter le risque d'anomalies immunitaires." } }, { "@type": "Question", "name": "Les expositions environnementales sont-elles un facteur ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines expositions environnementales peuvent affecter la santé des thymocytes." } } ] } ] }

Sources (10000 au total)

Plerixafor and resatorvid inhibit hepatitis B virus

An increase in the demand for a functional cure has accelerated research on new methods of therapy for chronic hepatitis B, which is mainly focused on restoring antiviral immunity for controlling vira... In this study, we generated the Epro-LUC-HepG2 cell model for screening compounds that target EFTUD2. Plerixafor and resatorvid were screened from 261 immunity and inflammation-related compounds due t... The dual-luciferase reporter assays showed that the EFTUD2 promoter hEFTUD2pro-0.5 kb had the strongest activity. In Epro-LUC-HepG2 cells, plerixafor and resatorvid significantly upregulated the activ... We established a convenient model for screening compounds that target EFTUD2 and further identified plerixafor and resatorvid as novel HBV inhibitors...

Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment for several mature B-cell malignancies. Reactivation of hepatitis B virus (HBV) is a well-described complication in p... We report the first case of HBV reactivation during ibrutinib treatment in an asymptomatic 82-year-old woman with seronegative occult hepatitis B patient (i.e., negative for HBsAg, anti-HBc and anti-H... Our case illustrated that in populations with a high incidence of HBV exposure, systematic screening for HBV exposure is essential prior to ibrutinib treatment, followed by serial monitoring of serolo...

The Investigation of Hepatitis B Vaccine Immune Responses in Occult Hepatitis B Virus-Infected Patients.

There is no effective treatment for occult hepatitis B virus infection (OBI) patients, and immunotherapy may be one of the most promising options. We aim to investigate the underlying mechanism and th... Outpatient OBI patients were screened and randomly divided into treatment (Group A) and control (Group B) groups. At weeks 0, 4, and 24, patients in Group A received a subcutaneous/intramuscular injec... Of the 228 OBI patients, 28 were excluded, and 200 were enrolled for observation. In the end, 44 patients were included in Group A and 39 in Group B after excluding lost cases. At week 0 (baseline), s... Anti-HBs in Group A patients were positively correlated with B lymphocytes (r=0.3431, 0.3087, and 0.3041, respectively) and positively correlated with CD8... Virological reactivation is a risk for OBI patients. Serum hepatitis B surface antibodies were significantly increased after hepatitis B vaccine treatment, the same as the numbers of peripheral blood ...

Hepatitis B virus X gene impacts on the innate immunity and immune-tolerant phase in chronic hepatitis B virus infection.

The immunologic features involved in the immune-tolerant phase of chronic hepatitis B (CHB) virus (HBV) infection are unclear. The hepatitis B virus X (HBx) protein disrupts IFN-β induction by downreg... Children with CHB in the immune-tolerant phase were recruited and followed longitudinally. HBx gene sequencing of infecting HBV strains was performed, and the effects of HBx mutations on the immune-to... A total of 173 children (median age, 6.92 years) were recruited. Patients carrying HBx R87G, I127V and R87G + I127V double mutations exhibited higher cumulative incidences of immune-tolerant phase bre... HBx suppresses IFN-β induction. R87G and I127V mutation restored IFN-β production by preventing MAVS degradation, contributing to curtailing the HBV immune-tolerant phase in CHB patients....

Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.

Hepatitis B virus (HBV)-human Immunodeficiency virus (HIV) co-infection promotes an aggressive disease course of HBV infection. In the only available non-Cochrane systematic review on antiviral therap... To evaluate the benefits and harms of tenofovir-based antiviral combination regimens versus placebo, tenofovir alone, or non-tenofovir-based antiviral regimen either alone or in combination with HBV f... We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane Central Register of Controlled Trials, MEDLINE Ovid, Embase Ovid, LILACS (Bireme), Science Citation Index Expanded (W... We aimed to include randomised clinical trials comparing tenofovir-based antiviral combination regimens (anti-HIV regimen with lopinavir-ritonavir therapy, or any other antiviral therapy, and two drug... We used standard methodological procedures expected by Cochrane. Primary outcomes included all-cause infant mortality, proportion of infants with serious adverse events, proportion of infants with HBV... Five completed trials were included, of which four trials contributed data to one or more of the outcomes. They included a total of 533 participants randomised to tenofovir-based antiviral combination... We do not know what the effects of tenofovir-based antiviral combination regimens are on all-cause infant mortality, proportion of infants with serious adverse events and proportion of mothers with se...